Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
German MS Register by the German MS Society, MS Research and Project Development gGmbH [MSFP], Hannover, Germany.
J Neurol. 2024 Jun;271(6):3409-3416. doi: 10.1007/s00415-024-12286-4. Epub 2024 Mar 22.
Persons with MS (PwMS) ≥ 55 years are underrepresented in therapy studies leading to a lack of evidence.
To study the subgroup of PwMS ≥ 55 years in the German MS registry in comparison with PwMS < 55 years. Endpoints of interest were the grade of disability, leading symptoms, clinical and magnetic resonance imaging activity, and use of disease modifying therapy.
At the time of analysis, data from 40,428 PwMS were available for analysis. In PwMS aged ≥ 65 and PwMS aged ≥ 55 to 64 years, compared with PwMS aged < 55 years, the mean Expanded Disability Status Scale Scores were higher (5.3, 4.2 and 2.7, respectively), while the proportion of individuals with current use of disease modifying therapy was lower (42.6%, 60.9% and 76.7%, respectively). The older patient groups were more likely to be labeled with progressive MS and the frequency of occupational invalidity was high (38.8% in PwMS aged ≥ 55 to 64 years). Gait disorder, fatigue, bladder dysfunction, and spasticity were among the leading symptoms in PwMS aged ≥ 55 years.
PwMS ≥ 55 years have a high degree of disability, but a large proportion do not receive disease modifying therapy, exposing an unmet need.
55 岁及以上的多发性硬化症（MS）患者在治疗研究中代表性不足，导致证据不足。
在德国 MS 登记处研究 55 岁及以上的 MS 患者亚组，并与<55 岁的 MS 患者进行比较。感兴趣的终点是残疾程度、主要症状、临床和磁共振成像活动以及疾病修正治疗的使用。
在分析时，有 40428 名 MS 患者的数据可用于分析。与<55 岁的 MS 患者相比，65 岁及以上和 55 岁至 64 岁的 MS 患者的扩展残疾状态量表评分更高（分别为 5.3、4.2 和 2.7），而当前使用疾病修正治疗的比例较低（分别为 42.6%、60.9%和 76.7%）。年龄较大的患者群体更有可能被诊断为进展型 MS，职业能力丧失的频率较高（55 岁至 64 岁的 MS 患者中为 38.8%）。步态障碍、疲劳、膀胱功能障碍和痉挛是 55 岁及以上 MS 患者的主要症状之一。
55 岁及以上的 MS 患者残疾程度较高，但很大一部分患者未接受疾病修正治疗，存在未满足的需求。
Zotero 插件